Off-Label Use of Drugs in Children
The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants,...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 2014-03, Vol.133 (3), p.563-567 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 3 |
| container_start_page | 563 |
| container_title | Pediatrics (Evanston) |
| container_volume | 133 |
| creator | NEVILLE, Kathleen A |
| description | The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants, children, and adolescents, because an overwhelming number of drugs still have no information in the labeling for use in pediatrics. The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term "off-label" does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient. |
| doi_str_mv | 10.1542/peds.2013-4060 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1504162733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A370923969</galeid><sourcerecordid>A370923969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-49dc7ba3c644b95a7899e964a3ce33cca0ca3b90c13832257d50a330c82b93f33</originalsourceid><addsrcrecordid>eNpd0M9LwzAUB_Agips_rh6lKIKXzpe8pG2OY_6EwS56Dmmazo6snckK-t-bsqng6cHj8x5fvoRcUJhQwdndxlZhwoBiyiGDAzKmIIuUs1wckjEA0rgHMSInIawAgIucHZMR4yLLAeSYXC3qOp3r0rrkLdikq5N73y9D0rTJ7L1xlbftGTmqtQv2fD9Pydvjw-vsOZ0vnl5m03lqYpBtymVl8lKjyTgvpdB5IaWVGY8bi2iMBqOxlGAoFsiYyCsBGhFMwUqJNeIpud393fjuo7dhq9ZNMNY53dquD4oK4DRjOQ70-h9ddb1vY7pBCeRUoIgq3amldlY1renarf3cms45u7Qqhp8t1BRzkAxlJqOf7LzxXQje1mrjm7X2X4qCGtpWQ9tqaFsNbceDy32Mvlzb6pf_1BvBzR7oYLSrvW5NE_5cgVRmCPgN0fWCqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505341535</pqid></control><display><type>article</type><title>Off-Label Use of Drugs in Children</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>NEVILLE, Kathleen A</creator><creatorcontrib>NEVILLE, Kathleen A ; American Academy of Pediatrics Committee on Drugs ; COMMITTEE ON DRUGS ; MMM</creatorcontrib><description>The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants, children, and adolescents, because an overwhelming number of drugs still have no information in the labeling for use in pediatrics. The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term "off-label" does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2013-4060</identifier><identifier>PMID: 24567009</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>Elk Grove Village, IL: American Academy of Pediatrics</publisher><subject>Biological and medical sciences ; Child ; Children ; Children & youth ; Decision making ; Drug therapy ; Drugs ; General aspects ; Health aspects ; Humans ; Influence ; Judgment ; Medical sciences ; Off label prescribing ; Off-Label Use - legislation & jurisprudence ; Off-Label Use - standards ; Pediatrics ; Pediatrics - legislation & jurisprudence ; Pediatrics - methods ; Pediatrics - standards ; Prescription drugs ; United States ; United States Food and Drug Administration - legislation & jurisprudence ; United States Food and Drug Administration - standards</subject><ispartof>Pediatrics (Evanston), 2014-03, Vol.133 (3), p.563-567</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright American Academy of Pediatrics Mar 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-49dc7ba3c644b95a7899e964a3ce33cca0ca3b90c13832257d50a330c82b93f33</citedby><cites>FETCH-LOGICAL-c542t-49dc7ba3c644b95a7899e964a3ce33cca0ca3b90c13832257d50a330c82b93f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28319630$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24567009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NEVILLE, Kathleen A</creatorcontrib><creatorcontrib>American Academy of Pediatrics Committee on Drugs</creatorcontrib><creatorcontrib>COMMITTEE ON DRUGS</creatorcontrib><creatorcontrib>MMM</creatorcontrib><title>Off-Label Use of Drugs in Children</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants, children, and adolescents, because an overwhelming number of drugs still have no information in the labeling for use in pediatrics. The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term "off-label" does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient.</description><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Children</subject><subject>Children & youth</subject><subject>Decision making</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>General aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Influence</subject><subject>Judgment</subject><subject>Medical sciences</subject><subject>Off label prescribing</subject><subject>Off-Label Use - legislation & jurisprudence</subject><subject>Off-Label Use - standards</subject><subject>Pediatrics</subject><subject>Pediatrics - legislation & jurisprudence</subject><subject>Pediatrics - methods</subject><subject>Pediatrics - standards</subject><subject>Prescription drugs</subject><subject>United States</subject><subject>United States Food and Drug Administration - legislation & jurisprudence</subject><subject>United States Food and Drug Administration - standards</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0M9LwzAUB_Agips_rh6lKIKXzpe8pG2OY_6EwS56Dmmazo6snckK-t-bsqng6cHj8x5fvoRcUJhQwdndxlZhwoBiyiGDAzKmIIuUs1wckjEA0rgHMSInIawAgIucHZMR4yLLAeSYXC3qOp3r0rrkLdikq5N73y9D0rTJ7L1xlbftGTmqtQv2fD9Pydvjw-vsOZ0vnl5m03lqYpBtymVl8lKjyTgvpdB5IaWVGY8bi2iMBqOxlGAoFsiYyCsBGhFMwUqJNeIpud393fjuo7dhq9ZNMNY53dquD4oK4DRjOQ70-h9ddb1vY7pBCeRUoIgq3amldlY1renarf3cms45u7Qqhp8t1BRzkAxlJqOf7LzxXQje1mrjm7X2X4qCGtpWQ9tqaFsNbceDy32Mvlzb6pf_1BvBzR7oYLSrvW5NE_5cgVRmCPgN0fWCqA</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>NEVILLE, Kathleen A</creator><general>American Academy of Pediatrics</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Off-Label Use of Drugs in Children</title><author>NEVILLE, Kathleen A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-49dc7ba3c644b95a7899e964a3ce33cca0ca3b90c13832257d50a330c82b93f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Children</topic><topic>Children & youth</topic><topic>Decision making</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>General aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Influence</topic><topic>Judgment</topic><topic>Medical sciences</topic><topic>Off label prescribing</topic><topic>Off-Label Use - legislation & jurisprudence</topic><topic>Off-Label Use - standards</topic><topic>Pediatrics</topic><topic>Pediatrics - legislation & jurisprudence</topic><topic>Pediatrics - methods</topic><topic>Pediatrics - standards</topic><topic>Prescription drugs</topic><topic>United States</topic><topic>United States Food and Drug Administration - legislation & jurisprudence</topic><topic>United States Food and Drug Administration - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NEVILLE, Kathleen A</creatorcontrib><creatorcontrib>American Academy of Pediatrics Committee on Drugs</creatorcontrib><creatorcontrib>COMMITTEE ON DRUGS</creatorcontrib><creatorcontrib>MMM</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NEVILLE, Kathleen A</au><aucorp>American Academy of Pediatrics Committee on Drugs</aucorp><aucorp>COMMITTEE ON DRUGS</aucorp><aucorp>MMM</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Off-Label Use of Drugs in Children</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>133</volume><issue>3</issue><spage>563</spage><epage>567</epage><pages>563-567</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants, children, and adolescents, because an overwhelming number of drugs still have no information in the labeling for use in pediatrics. The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term "off-label" does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient.</abstract><cop>Elk Grove Village, IL</cop><pub>American Academy of Pediatrics</pub><pmid>24567009</pmid><doi>10.1542/peds.2013-4060</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 2014-03, Vol.133 (3), p.563-567 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1504162733 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Biological and medical sciences Child Children Children & youth Decision making Drug therapy Drugs General aspects Health aspects Humans Influence Judgment Medical sciences Off label prescribing Off-Label Use - legislation & jurisprudence Off-Label Use - standards Pediatrics Pediatrics - legislation & jurisprudence Pediatrics - methods Pediatrics - standards Prescription drugs United States United States Food and Drug Administration - legislation & jurisprudence United States Food and Drug Administration - standards |
| title | Off-Label Use of Drugs in Children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T04%3A29%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Off-Label%20Use%20of%20Drugs%20in%20Children&rft.jtitle=Pediatrics%20(Evanston)&rft.au=NEVILLE,%20Kathleen%20A&rft.aucorp=American%20Academy%20of%20Pediatrics%20Committee%20on%20Drugs&rft.date=2014-03-01&rft.volume=133&rft.issue=3&rft.spage=563&rft.epage=567&rft.pages=563-567&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2013-4060&rft_dat=%3Cgale_proqu%3EA370923969%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505341535&rft_id=info:pmid/24567009&rft_galeid=A370923969&rfr_iscdi=true |